Literature DB >> 7973890

Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease.

D Brookoff1.   

Abstract

Women discharged from a municipal emergency department with the diagnosis of pelvic inflammatory disease were surveyed by telephone about their compliance with a standard 10-day regimen of doxycycline. Of the 386 women who completed the survey, 31% reported complete compliance; 28% reported that they did not fill their prescriptions for doxycycline. The most common reasons given for not filling prescriptions were cost, resolution of symptoms, and inconvenience. Forty-one percent reported that they stopped their medication early (average 4.1 +/- 1.4 days). Lack of symptoms, persistence of symptoms, and side effects were the major reasons given for the discontinuation of medications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7973890     DOI: 10.1097/00007611-199411000-00006

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.

Authors:  J D C Ross; H S Cronjé; T Paszkowski; I Rakoczi; D Vildaite; A Kureishi; M Alefelder; P Arvis; P Reimnitz
Journal:  Sex Transm Infect       Date:  2006-05-24       Impact factor: 3.519

Review 2.  Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.

Authors:  A P Lea; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

3.  Treatment of Chlamydia trachomatis infections in pregnant women.

Authors:  J M Miller; D H Martin
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

4.  Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001.

Authors:  Mariaelena D Jefferds; Kayla Laserson; Alicia M Fry; Sharon Roy; James Hayslett; Laurence Grummer-Strawn; Laura Kettel-Khan; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.